The U.S. FDA has approved
Farxiga (dapaglifozin) tablets for
adults with type 2 diabetes.
Dapaglifozin propanediol
monohydrate was approved in
Australia under specific conditions
on 05 Oct 2012 and sponsored by
Bristol-Myers Squibb.
Farxiga had been rejected in the
US previously over safety concerns
but an outside advisory panel said
the benefits outweighed the risks,
Reuters reported.
The Australian submission details
can be viewed by CLICKING HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Jan 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Jan 14
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
THE University of South Australia has released a new study to help healthcare workers better support women with persistent pelvic pain, including symptoms that are suggestive of gynaecological, lower urinary tract, bowel, sexual, and pelvic floor dysfunction.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.